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Background.Capsaicin, one of several capsaicinoid compounds, is a potent TRPV1 agonist. Topical application at high concentration
(high concentration, >1%) induces a reversible disappearance of epidermal free nerve endings and is used to treat peripheral
neuropathic pain (PNP). While the benefit of low-concentration capsaicin remains controversial, the 8%-capsaicin patch
(Qutenza, 2010, Astellas, Netherlands) has shown its effectiveness. This patch is, however, costly and natural high-concentration
capsaicinoid solutions may represent a cheaper alternative to pure capsaicin. Methods. In this retrospective study, 149 patients
were screened, 132 were included with a diagnosis of neuropathic pain, and eighty-four were retained in the final analyses
(median age: 57.5 years [IQR25–75: 44.7–67.1], male/female: 30/54) with PNP who were treated with topical applications of natural
high-concentration capsaicinoid solutions (total number of applications: 137). Indications were postsurgical PNP (85.7%) and
nonsurgical PNP (14.3%) (posttraumatic, HIV-related, postherpetic, and radicular PNP). Objectives. To assess the feasibility of
topical applications of natural high-concentration capsaicinoid solutions for the treatment of PNP.Results.Themedian treated area
was 250 cm2 [IQR25–75: 144–531]. The median amount of capsaicinoids was 55.1mg [IQR25–75: 28.7–76.5] per plaster and the
median concentration was 172.3𝜇g/cm2 [IQR25–75: 127.6–255.2]. Most patients had local adverse effects on the day of treatment,
such as mild to moderate burning pain and erythema. 13.6–19.4% of the patients experienced severe pain or erythema. Following
treatment, 62.5% of patients reported a lower pain intensity or a smaller pain surface, and 35% reported a sustained pain relief
lasting for at least 4 weeks. Conclusion. Analgesic topical treatment with natural high-concentration capsaicinoid is feasible and
may represent a low cost alternative to alleviate PNP in clinical practice.
1. Introduction
Peripheral neuropathic pain (PNP) results from disease,
damage, or dysfunction of the somatosensory system [1]. Its
multiple aetiologies include postsurgical neuropathies, post-
traumatic neuropathies, painful diabetic polyneuropathies,
postherpetic neuralgia (PHN), and HIV-associated neu-
ropathies (HIV-AN) [1]. Epidemiologic data from Europe
show that 7–10% of the population is affected by pain with
neuropathic characteristics [2]. Nowadays it remains a diffi-
cult condition to treat [3] and current systemic treatments
like tricyclic antidepressants, serotonin/norepinephrine reu-
ptake inhibitors, anticonvulsants, or opioids provide only
moderate pain relief while causing several adverse drug
reactions like nausea, dizziness, and somnolence [4]. Topical
treatment with capsaicin has been suggested as an interesting
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alternative way to treat PNP, because it has few significant
systemic effects [5], and presents only rare adverse reactions
except for local-application burning pain and erythema [6].
The genus Capsicum includes species commonly called
“pepper” plants and “chilli” peppers. The first recorded
use dates back to 3000 BC [7]. The spiciness is due to
lipophilic chemicals called capsaicinoids of which the most
potent is capsaicin (8-methyl-N-vanillyl-6-nonenamide).
Other related compounds, found in chilli peppers, include
dihydrocapsaicin, homodihydrocapsaicin, homocapsaicin,
nordihydrocapsaicin, and nonivamide [8]. Since topical
application of capsaicinoids produces a burning sensation,
which has been widely used in animal research on models of
chemically induced pain, Capsicum extracts have also been
used as a topical analgesic in traditional medicine. In some
countries, low concentration (<1%) of capsaicin creams is
available over the counter for muscle or rheumatism, but
several daily applications for months are required, thereby
creating concerns with efficacy and compliance [9].
The pharmaceutical effects of topical capsaicin applica-
tions are based on their action as agonists of Transient Recep-
tor Potential Vanilloid receptor, subtype 1 (TRPV1), which is
a ligand-controlled, nonselective cation channel expressed on
nociceptive fibers [10]. TRPV1s are heat-sensitive receptors,
activated at temperatures between 37 and 45∘C. Expressed
at the level of free nerve endings, their activation causes
a burning pain sensation. TRPV1s can also be activated
at basal temperatures when they are bound by exogenous
ligands such as capsaicin [11]. Nerve damage causes the
upregulation of TRPV1s expression in injured C-fibers, which
leads to a pathological amplification in the transduction of
heat signals, interpreted as pain [11]. A single application
of high-concentration capsaicin or repeated applications of
low concentration triggers a desensitization of TRPV1s-
expressing free nerve endings through a yet unexplained
mechanism. This leads to a temporary retraction or destruc-
tion of epidermal free nerve endings.The result is a reduction
of nociceptive input from the treated region, possibly leading
to a reduction of pain in PNP [12, 13]. However, topical
application of capsaicin also causes a transient local erythema
due to the release of neuropeptides during the capsaicin-
induced neurogenic inflammation [14].
High-concentration patches of pure capsaicin 8% (Qute-
nza, Astellas) have been available inmost European countries
since 2009. The European Union approved the patches for
the treatment of PNP in nondiabetic adults, to be used either
alone or in combination with other medical products [15]. It
has been studied in several clinical trials for PHN [16, 17],
HIV-AN [18, 19], in prospective analysis for general PNP [6].
These trials have all shown significant 30–40% reductions
in pain scores that were maintained over an 8-week period
after a single application, although the high cost of the
patches (over 300€ per patch in Belgium) currently limits
their clinical use.
This retrospective analysis with commercially available
natural high-concentration capsaicinoid solutions aims to
determine the feasibility of using these as an alternative low
cost topical treatment for PNP.
2. Materials and Methods
This study was conducted in the Pain Clinic of the Saint-
Luc University Hospital (Cliniques Universitaires Saint-Luc,
Brussels, Belgium) with the agreement of the ethical commit-
tee (Ethical number approval: 2014/20MAI/267, chairperson:
Prof. Jean-Marie Maloteaux). It took place between January
2013 and December 2014 and involved 84 patients. All
patients were treated with an application of natural high-
concentration capsaicinoid solution. Only patients suffering
from definite PNP (according to the IASP criteria, first
described by Treede et al.) were considered. These criteria are
plausible neuroanatomical distribution, appropriate history,
altered sensory signs, and evidence of lesion or disease [20].
We included patients being 17 years old and older and patients
with diabetes. Patients were excluded (𝑛 = 48) if they were
found not to suffer fromPNP, aQutenza patch was previously
used, the medical file was incomplete, and the follow-up
was missing. As this study is a retrospective analysis, all the
patients were treated according to their need, independently
of this study.
Two different natural high-concentration capsaicinoid
solutions were used (Chilli extract, Wirrmann, UK). As
their exact contents were not given by the manufacturers,
we decided to have them analysed using High-Performance
Liquid Chromatography (HPLC) coupled to a UV detector
at the Pharmacognosy Research Group of the University
(Louvain Drug Research Institute, LDRI, Brussels, Belgium).
TheHPLCwas performed following a validatedmethodology
described in the European pharmacopeia (capsici oleoresina
raffinata et normata) [21] using a LaChrom Elite HPLC
integrated system (Merck Hitachi, VWR, Leuven, Belgium)
equipped with a L-2450 UV detector, a L-2300 oven, L-
2130 autosampler, and L-2130 pump,with EZChrom software.
Isocratic elution was used with Agilent Zorbax Eclipse XDB
phenyl 250mm× 4.6mmcolumn (5 𝜇M).TheHPLCanalysis
of the capsicum extracts showed that the first solution used
contained 0.71% of total capsaicinoid and the second solution
2.01%.
Patients were treated with a plaster gauze, adjusted
to the painful area previously drawn on the skin. Before
applying the gauze onto the skin, it was impregnated with
capsaicinoid solution. Ten patients were treated with the
first solution and 53 with the second one. The median area
per application was 250 cm2 [IQR25–75: 144–531] and the
median amounts of solution per application were 100 drops
[IQR25–75: 50–155], or 2.8mL [IQR25–75: 1.4–4.4].The skin
region to be treated was always intact and dried before the
plaster was applied by an anaesthesiologist. An intravenous
catheter was placed before treatment for safety and pain
management. Patients were premedicated with 5% lidocaine
gel on the target skin, lidocaine-infiltration, or tramadol
100mg, performed 60 minutes before plaster application.
After application, the plaster remained on the target skin for
60 minutes. Elastic bandages were used to improve adhesion
between the skin and plaster. After removal, the skin was
cleaned with a cleaning gel and cooled with a cold pack.
The duration of cooling depended on the patient’s needs and
patients were recommended to continue its use at home for
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several days, if necessary. Where the cold pack proved to
be insufficient, treatment-related discomfort was alleviated
before going home with paracetamol 1 g, tramadol 50mg, or
titrated IV morphine. Any adverse events were reported and
followed up until they were resolved and explained. After the
initial visit, follow-up visits were offered to the patients for
several weeks. A second capsaicinoid plaster was applied at
the next visit to the hospital if the pain threshold had risen
again after the initial relief, even if it was not as intense as
the first. A majority of the study subjects had concomitant
chronic medications. Some patients had painkillers which
were classified based on the analgesic ladder which has three
steps: paracetamol and nonsteroidal anti-inflammatory drugs
belong to the first step, tramadol and tilidine-naloxone belong
to the second, and morphine belongs to the third. Other
patients had current systemic treatments like tricyclic antide-
pressants, serotonin/norepinephrine reuptake inhibitors, or
anticonvulsants. Those chronic medications were kept and
reevaluated throughout the follow-up.
Pain levels were assessed before the treatment using a 0–
10Visual Analog Scale (VAS). Presence of neuropathic symp-
toms was assessed clinically by an anaesthesiologist (French
version of the DN4 questionnaire) [22]. Pain was evaluated
immediately after treatment to decide if a treatment-related
discomfort therapy was necessary. The pain characteristics to
the application were estimated during the follow-up visits.
We asked patients whether they had experienced a significant
pain reduction in terms of intensity and/or surface area over
time and asked them about their general impression of pain
change in terms of being positive (verbalized as good) or
negative (bad).
To assess the potential of the treatment, data from
subgroups of patients were analysed for differences in terms
of global impression of pain change, lower pain intensity, and
surface area after the first high-concentration capsaicinoid
plaster application. The cohorts of patients compared were
based on (i) the DN4 (DN4 < 4 versus DN4 ≥ 4); (ii)
the pain origins (non-post-surgical PNP versus postsurgical
PNP; post-total knee replacement PNP versus other PNP;
post-knee-surgery PNP versus other PNP); (iii) the premed-
ication given (tramadol versus other premedications); (iv)
the pain intensity and erythema reaction after application
(none or mild pain versus medium or strong pain); and (v)
the concentration of capsaicinoids given (<200𝜇g/cm2 or
≥200𝜇g/cm2).
Biometrical analysis followed statistical analysis rules.
Data were described as mean ± SD and median [IQR25–75]
when appropriate. Proportion, in percentage, was expressed
with 95% confidence interval (95%CI). Subgroup differences,
in terms of pre- and posttreatment pain scores per patient,
were analysed using Student’s qualitative t-test (paired 𝑡-test)
for independent-sample comparisons. Statistical analysis was
performed using R language (version 3.2.0).The threshold for
statistical significance level was set at 𝑝 < 0.05.
3. Results
One hundred and forty-nine patients were considered for
inclusion in this study. Seventeen were excluded for not
meeting the inclusion criteria regarding the diagnosis of neu-
ropathic pain. One hundred and thirty-two patients received
a total number of 291 applications of the natural high-
concentration capsaicinoid. Of these patients, evaluation files
were completed for 137 applications from 84 patients, 30 of
whom were males (35.7%) and 54 were females (64.3%). The
median age was 57.5 years [IQR25–75: 44.7–67.1].Themedian
baseline VAS pain score was 6 [IQR25–75: 5–7]. In seventy-
three patients, the DN4 questionnaire was complete, with a
median baseline DN4 score of 4 [IQR25–75: 3–6]. Fifty-one
patients scored ≥4, and twenty-four scored <4 (in which 4
patients scored 2). Of these patients, 14.3% had nonsurgical
PNPwhile 85.7%had postsurgical PNP. 52.4%of the previous
group received a knee surgery. The population is further
described in Table 1.
Based on the DN4 score, patients were asked to describe
their PNP and the results recorded on files. The most-often
used descriptors for pain were burning (73.2%), tingling
(73.2%), and pins and needles (62.5%). Clinical examination
indicated a tactile hyperesthesia, hyperalgesia, or allodynia
in 91.0% of patients (Table 2). Several concomitant med-
ications were taken by most of the patients for chronic
PNPbefore high-concentration capsaicinoid applicationwith
50.6% of patients having first-step painkillers, 40.0% having
second-step painkillers, 11.8% having third-step painkillers,
25.9% having anticonvulsants, and 15.3% having antide-
pressants. Only 5.9% of patients had no medication for
chronic pain (Table 3). Nonpharmacological pain therapies
were not reported. Taking into consideration the quantity of
capsaicinoid solution applied over the plasters, the median
capsaicinoid concentration was 172.3𝜇g/cm2 [IQR25–75:
127.6–255.2], with a median of 55.1mg [IQR25–75: 28.7–76.5]
of capsaicinoids per plaster. Before the high-concentration
capsaicinoid application, 85.4% of patients received tramadol
100mg (𝑛 = 41) while 8.3% had another premedication
such as topical-lidocaine (𝑛 = 1) and local anaesthetic
infiltration (𝑛 = 2). 6,3% (𝑛 = 3) did not receive any
premedication. Immediately after the application, evaluation
showed that most of the 132 patients had local adverse effects
with 83.3% of patients reporting mild or medium burning
pain (𝑛 = 66), 70.8% having mild or medium erythema
(𝑛 = 72), and only 13.6% having strong burning pain and
19.4% having strong erythema (Figure 1). Treatment-related
side effects required a cold pack in 69.8% of the cases. Only
7.0% of patients required an additional second- or third-step
painkiller.
The follow-up visits, several weeks after the application,
showed that 62.5% of the 132 patients had a positive global
impression of pain change (𝑛 = 80).Within this group, 75.0%
reported a decrease in their pain intensity (𝑛 = 44) and
86.1% reported a decrease in their pain surface area (𝑛 = 36)
(Figure 2). We did not identify any predictive factor for the
effect of the treatment after looking for differences between
the subgroups previously described, especially regarding the
value of the DN4, or the presence of a score more or less
than 4 before the treatment (𝑝 > 0.05 for all the compar-
isons).
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Table 1: Characteristics of patients (𝑛 = 84).
Demographical and clinical data Value
Patients 84
Male, 𝑛 (%) 30 (35.7%)
Female, 𝑛 (%) 54 (64.3%)
Age, years, median [IQR25–75] 57.5 [44.5–67.1]
Baseline VAS score, median [IQR25–75] 6 [5–7]
Baseline DN4 score, median [IQR25–75] 4 [3–6]
Polyneuropathies diagnosis 𝑛 %
(I) Non-post-surgical PNP
(a) Posttraumatic neuropathy without
surgery 4 4.8
(b) HIV-associated neuropathy 1 1.2
(c) Foot diabetic polyneuropathy 1 1.2
(d) Radiculopathy 2 2.4
(e) Postherpetic neuralgia 2 2.4
(f) Other 2 2.4
Total of nonsurgical PNP 12 14.3
(II) Postsurgical PNP
(a) Postthoracotomy or thoracoscopy 9 10.7
(b) Postparietal surgery 3 3.6
(c) Postabdominal surgery 4 4.8
(d) Postback surgery 5 6.0
(e) Other 3 3.6
(f) Posttraumatic surgery (except knee) 4 4.8
(g) Posttotal knee replacement 31 36.9
(h) Posttraumatic knee surgery 4 4.8
(i) Post-other knee surgery 9 10.7
Total of knee surgeries 44 52.4
Total of postsurgical neuropathies 72 85.7
Localizations of pain, multiple responses
possible 𝑛 %
Knee 45 53.6
Hemithorax 13 15.5
Foot 9 10.7
Back 5 6.0
Abdomen 4 4.8
Other 4 4.8
Leg 3 3.6
Ankle 3 3.6
4. Discussion
This analysis confirms the feasibility of natural high-con-
centration capsaicinoid applications as a treatment of PNP
in clinical practice. As a retrospective study, this analysis is
limited by the lack of a control group and can therefore not
be used for the assessment of treatment effectiveness.
The population sample was relatively homogeneous with
85.7% of patients suffering from postsurgical PNP. This
homogeneity is due to the fact that most of our patients were
Table 2: Patients’ pain descriptions and pain clinical examinations
at baseline.
Patients’ descriptions at baseline 𝑛 %
(i) Burning (𝑛 = 52) 41 73.2
(ii) Tingling (𝑛 = 50) 41 73.2
(iii) Pins and needles (𝑛 = 44) 35 62.5
(iv) Electric shock sensation (𝑛 = 47) 33 58.9
(v) Numbness (𝑛 = 41) 29 51.8
(vi) Itching (𝑛 = 33) 17 48.5
(vii) Waking-up pain (𝑛 = 46) 25 44.6
(viii) Painful cold sensation (𝑛 = 34) 21 37.5
Clinical examinations at baseline
Hypoesthesia/hypoalgesia:
(i) Tactile (𝑛 = 42) 28 66.7
(ii) Pricking (𝑛 = 38) 24 63.2
(iii) Thermal (𝑛 = 43) 25 58.1
Hyperesthesia/hyperalgesia/allodynia
(i) Tactile (𝑛 = 67) 61 91.0
(ii) Thermal (𝑛 = 25) 24 61.5
(iii) Pricking (𝑛 = 24) 21 56.8
Table 3: Concomitant medications for PNP at baseline (𝑁 = 84),
multiple responses possible.
𝑛 %
First-step painkillers 43 50.6
Second-step painkillers 34 40.0
Third-step painkillers 10 11.8
Anticonvulsants 22 25.9
Antidepressants 13 15.3
Other medications 10 11.8
No medication 5 5.9
being sent by orthopaedic and cardiovascular surgeons.How-
ever, even if all the patients met the IASP criteria for definite
neuropathic pain, a recent consensus of the NeuPSIG group
report that, without additional investigations, the presence of
neuropathic pain can only be seen as “probable” to “definite”
[23]. Of note, seeing the presence of an “appropriate history”
and the “presence of lesion or disease,” we considered a
high a priori probability for the presence of a neuropathic
pain. Thus, we used the DN4 questionnaire as an additional
assessment tool and found a DN4 less than 4 in a significant
proportion of the patients, which is questionable. But inmost
of these patients, only one item was missing, and some of the
patientswith amissingDN4mayhave higher scores. Anyway,
we did not find any difference in terms of efficacy of the
treatment associated with DN4 criteria, as being DN4 < 4
versus DN4 ≥ 4.
Despite some clear variability in our results, the quantity
of capsaicinoids per application was relatively high because of
the large amounts of solution used to impregnate the plasters
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Figure 1: High-concentration capsaicinoid application tolerability
immediately after treatment. Proportion (%) of treatment-related
discomfort in terms of burning pain (66 patients) or erythema in
(72 patients) ranked in order of intensity (IC = 95%).
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Figure 2: Peripheral neuropathic pain evolution, weeks after high-
concentration capsaicinoid treatment. Proportion (%) of change
in terms of pain intensity (44 patients) and pain surface area (36
patients) in the group of satisfied patients (IC = 95%).
(about 2.8mL per application). We believe this variability
may be easily reduced by establishing a standardised table
of number of drops per standard-sized plaster (drop/cm2).
In comparison to our median amounts of capsaicinoids
per application of 55.1mg [IQR25–75: 28.7–76.5], the high-
concentration Qutenza has a concentration of 640𝜇g/cm2
and 179mg of capsaicin per plaster [24], and the low-
concentration Zostrix cream 0.075% has around 3mg of
capsaicin per application [25], which makes our application
3.2 less strong than the high-concentration one but at least
18.2 times stronger than the low-concentration one (Table 4).
The application of high-concentration capsaicinoids was
generally well-tolerated, with 6.9% of patients needing a
treatment-related-discomfort medication to alleviate the side
effects in comparison to the 15–44% often reported in clinical
trials [6, 16–19]. Only burning sensations and erythema were
reported as side effects, the treatment of which was easily
manageable.
Table 4: Characteristics of high-concentration capsaicinoid appli-
cations.
Median capsaicinoid concentration per
application 𝜇g/cm
2 [IQR25–75]
(i) In 2013 (𝑛 = 10) 90.0 [51.0–123.0]
(ii) In 2014 (𝑛 = 53) 255.0 [144.0–262.5]
(iii) Total (𝑛 = 63) 172.3 [126.7–255.2]
Median weight of capsaicinoid per
application mg
(i) In 2013 (𝑛 = 10) 51.0 [25.0–71.0]
(ii) In 2014 (𝑛 = 53) 55.0 [29.0–75.5]
(iii) Total (𝑛 = 63) 55.1 [28.7–76.5]
Median surface area per application, cm2
(𝑛 = 67) 250.0 [144.0–531.0]
Median amount of mL per application,
mL (𝑛 = 63) 100.0 [1.4–4.4]
Although the aim of our study was not to assess the
efficacy of high-concentration capsaicinoids and the results
did not have enough power to allow a statistical assessment
of clinical efficacy, the emerging trends for pain reduction
in global impression of change observed in this study seem
to be comparable to that found in previous RCTs on high-
concentration capsaicin [6, 16–19]. One important differ-
ence with the commercially available high-concentration
capsaicin patch (Qutenza, Astellas) is the cost. Indeed, even
if available from 2009 in Europe, the high cost (more than
300€) without reimbursement in some countries (as in Bel-
gium) renders its use nonpracticable. We did not performed
cost-effectiveness analysis. But the demonstrated feasibility of
the use of present alternative (natural extract, costing only
a few euros), warrants further investigations, especially to
facilitate the quality control before potential diffusion.
5. Conclusions
In conclusion, this retrospective study showed that topical
treatment of PNP using natural high-concentration capsaici-
noid applications is feasible, with generally mild to moderate
and short-lasting side effects. This low cost alternative may
constitute a new opportunity to widen the topical treatments
available for patients suffering from PNP.
Competing Interests
The authors declared no competing interests. This work
is partially financed by the Wallonia Region of Belgium
(Program DG06) and by the Department of Anesthesiology
of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Authors’ Contributions
Fanny Bauchy, Andre Mouraux, Ronald Deumens, Mar-
jolein Leerink, Antonio Ulpiano Trillig, Bernard le Polain
de Waroux, Arnaud Steyaert, Quetin-Leclercq Joe¨lle, and
6 Pain Research and Management
Patrice Forget were involved in study concept and design;
Fanny Bauchy, Antonio Ulpiano Trillig, Bernard le Polain
de Waroux, Arnaud Steyaert, Quetin-Leclercq Joe¨lle, and
Patrice Forget were involved in acquisition of subjects and/or
data; Fanny Bauchy and Patrice Forget analysed the data;
all the authors participated in the interpretation of data and
preparation of manuscript and approved its final version.
Acknowledgments
The authors would like to thank Richard Gowen for his help
in the edition for syntax.
References
[1] R. Baron, A. Binder, andG.Wasner, “Neuropathic pain: diagno-
sis, pathophysiological mechanisms, and treatment,”The Lancet
Neurology, vol. 9, no. 8, pp. 807–819, 2010.
[2] O. Van Hecke, S. K. Austin, R. A. Khan, B. H. Smith, and
N. Torrance, “Neuropathic pain in the general population: a
systematic review of epidemiological studies,” Pain, vol. 155, no.
4, pp. 654–662, 2014.
[3] N. Attal, “Neuropathic pain: mechanisms, therapeutic ap-
proach, and interpretation of clinical trials,” CONTINUUM
Lifelong Learning in Neurology, vol. 18, no. 1, pp. 161–175, 2012.
[4] A. B. O’Connor and R. H. Dworkin, “Treatment of neuropathic
pain: an overview of recent guidelines,” American Journal of
Medicine, vol. 122, no. 10, pp. S22–S32, 2009.
[5] K. Horva´th,M. Boros, T. Bagoly et al., “Analgesic topical capsai-
cinoid therapy increases somatostatin-like immunoreactivity in
the human plasma,” Neuropeptides, vol. 48, no. 6, pp. 371–378,
2014.
[6] C. Maihofner andM.-L. Heskamp, “Prospective, non-interven-
tional study on the tolerability and analgesic effectiveness over
12 weeks after a single application of capsaicin 8% cutaneous
patch in 1044 patients with peripheral neuropathic pain: first
results of the QUEPP study,” Current Medical Research and
Opinion, vol. 29, no. 6, pp. 673–683, 2013.
[7] M. Schumacher, “TRP channels in pain and inflammation:
therapeutic opportunities,” Pain Practice, vol. 10, pp. 185–200,
2010.
[8] X.-J. Luo, J. Peng, and Y.-J. Li, “Recent advances in the study on
capsaicinoids and capsinoids,” European Journal of Pharmacol-
ogy, vol. 650, no. 1, pp. 1–7, 2011.
[9] J. F. Peppin andM. Pappagallo, “Capsaicinoids in the treatment
of neuropathic pain: a review,”Therapeutic Advances in Neuro-
logical Disorders, vol. 7, no. 1, pp. 22–32, 2014.
[10] D. N. Cortright and A. Szallasi, “TRP channels and pain,”
Current Pharmaceutical Design, vol. 15, no. 15, pp. 1736–1749,
2009.
[11] D. Spicarova and J. Palecek, “The role of spinal cord vanilloid
(TRPV1) receptors in pain modulation,” Physiological Research,
vol. 57, supplement 3, pp. S69–S77, 2008.
[12] H. Knotkova, M. Pappagallo, and A. Szallasi, “Capsaicin
(TRPV1 agonist) therapy for pain relief: farewell or revival?”
Clinical Journal of Pain, vol. 24, no. 2, pp. 142–154, 2008.
[13] A. B. Malmberg, A. P. Mizisin, N. A. Calcutt, T. Von Stein,
W. R. Robbins, and K. R. Bley, “Reduced heat sensitivity
and epidermal nerve fiber immunostaining following single
applications of a high-concentration capsaicin patch,” Pain, vol.
111, no. 3, pp. 360–367, 2004.
[14] J. Winter, S. Bevan, and E. A. Campbell, “Capsaicin and pain
mechanisms,” British Journal of Anaesthesia, vol. 75, no. 2, pp.
157–168, 1995.
[15] P. L. McCormack, “Capsaicin dermal patch: in non-diabetic
peripheral neuropathic pain,” Drugs, vol. 70, no. 14, pp. 1831–
1842, 2010.
[16] G. A. Irving, M. M. Backonja, E. Dunteman et al., “A mul-
ticenter, randomized, double-blind, controlled study of NGX-
4010, a high-concentration capsaicin patch, for the treatment of
postherpetic neuralgia,” PainMedicine, vol. 12, no. 1, pp. 99–109,
2011.
[17] M. Backonja, M. S. Wallace, E. R. Blonsky et al., “NGX-4010,
a high-concentration capsaicin patch, for the treatment of
postherpetic neuralgia: a randomised, double-blind study,”The
Lancet Neurology, vol. 7, no. 12, pp. 1106–1112, 2008.
[18] D. M. Simpson, S. Gazda, S. Brown et al., “Long-term safety
of NGX-4010, a high-concentration capsaicin patch, in patients
with peripheral neuropathic pain,” Journal of Pain and Symptom
Management, vol. 39, no. 6, pp. 1053–1064, 2010.
[19] D. B. Clifford, D. M. Simpson, S. Brown et al., “A random-
ized, double-blind, controlled study of NGX-4010, a capsaicin
8% dermal patch, for the treatment of painful hiv-associated
distal sensory polyneuropathy,” Journal of Acquired Immune
Deficiency Syndromes, vol. 59, no. 2, pp. 126–133, 2012.
[20] R.-D. Treede, T. S. Jensen, J. N. Campbell et al., “Neuropathic
pain: redefinition and a grading system for clinical and research
purposes,” Neurology, vol. 70, no. 18, pp. 1630–1635, 2008.
[21] EDQM, The European Pharmacopea, EDQM, Strasbourg,
France, 8th edition, 2014.
[22] D. Bouhassira, N. Attal, H. Alchaar et al., “Comparison of
pain syndromes associatedwith nervous or somatic lesions and
development of a new neuropathic pain diagnostic question-
naire (DN4),” Pain, vol. 114, no. 1-2, pp. 29–36, 2005.
[23] O. van Hecke, P. R. Kamerman, N. Attal et al., “Neuropathic
pain phenotyping by international consensus (NeuroPPIC) for
genetic studies: a NeuPSIG systematic review, Delphi survey,
and expert panel recommendations,” Pain, vol. 156, no. 11, pp.
2337–2353, 2015.
[24] Astellas Pharma, Qutenza 179Mg Cutaneous Patch, EMC, 2014,
https://www.medicines.org.uk/emc/medicine/23156.
[25] AFT Pharmaceuticals, Zostrix HP, Capsaicin USP 0.075% w/w
Topical Cream, 2011, http://www.medsafe.govt.nz/profs/data-
sheet/z/ZostrixHPCr.pdf.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
